For those of you with the $20/month Chat GPT account

[Darryl]

For those of you with the $20/month Chat GPT account, please test the following version of Cancer Copilot and tell me what your experience with it is. Here's the link: chat.openai.com/g/g-uZwsIeK...

You can post your reply below or email me darrylm at malecare.org Thanks.

[Boonster]

Thanks for the link. I just took a quick look at Cancer Copilot. I can see it becoming an enormously useful tool. Boon--

[Darryl Partner in reply to Boonster]

Thank you!

[Boonster in reply to Darryl]

Here's a quick Q&A with Cancer Copilot below. Gave me a sense of how it approaches questions. I asked it about the survival benefits those of us on Orgovyx can expect:

Cancer Copilot: I conducted a search regarding the survival benefits of Orgovyx (relugolix) but was unable to find specific data on overall survival benefits from the HERO trial or other recent studies within the time allotted. However, I did find some relevant information about the effectiveness and safety profile of Orgovyx from the HERO trial:

Effectiveness: In the HERO trial, which involved more than 900 men with advanced prostate cancer, 97% of men treated with Orgovyx achieved and maintained very low testosterone levels through 48 weeks, compared to 89% of men who received leuprolide, another common treatment. This shows a superiority in the effectiveness of Orgovyx in achieving testosterone suppression, which is crucial in the treatment of hormone-sensitive prostate cancer.

Cardiovascular Safety: A significant finding from the HERO trial was that Orgovyx had a better cardiovascular safety profile compared to leuprolide. Specifically, the incidence of major adverse cardiovascular events was 2.9% in the Orgovyx group compared to 6.2% in the leuprolide group. This difference was even more pronounced in men with a history of heart problems.

Testosterone Recovery: Another important aspect of the HERO trial was the observation that testosterone levels returned to normal faster after stopping androgen deprivation therapy with Orgovyx compared to leuprolide. This is considered beneficial because prolonged testosterone suppression can lead to significant side effects.

While these points highlight the effectiveness and safety profile of Orgovyx, they do not directly answer your question about the specific survival benefit in terms of a percentage. For the most accurate and up-to-date information on overall survival benefits, I recommend consulting with your healthcare provider or oncologist, who may have access to the latest research and data.

Would you like me to suggest any further questions you might consider asking your doctor about Orgovyx and its impact on survival in advanced prostate cancer?

[Darryl Partner in reply to Boonster]

Thanks for posting this! Feedback helps me refine it.